| Name | Niraparib metabolite M1 |
|---|---|
| Synonyms |
2-{4-[(3S)-3-Piperidinyl]phenyl}-2H-indazole-7-carboxylic acid
2H-Indazole-7-carboxylic acid, 2-[4-[(3S)-3-piperidinyl]phenyl]- |
| Description | Niraparib metabolite M1 is a metabolite of niraparib, and the latter one acts as a novel poly(ADP-Ribose) polymerase (PARP) inhibitor. |
|---|---|
| Related Catalog | |
| In Vitro | Niraparib metabolite M1 has the validation in plasma and urine for the support of clinical studies such as the mass balance study and the absolute bioavailability study[1]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 442.0±45.0 °C at 760 mmHg |
| Molecular Formula | C19H19N3O2 |
| Molecular Weight | 321.373 |
| Flash Point | 221.1±28.7 °C |
| Exact Mass | 321.147736 |
| LogP | 4.01 |
| Vapour Pressure | 0.0±1.1 mmHg at 25°C |
| Index of Refraction | 1.693 |
| Storage condition | 2-8℃ |